Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
J Clin Endocrinol Metab. 2021 Mar 8;106(3):697-707. doi: 10.1210/clinem/dgaa904.
Little is known about how exogenous testosterone (T) affects the steroid profile in women. More knowledge would give the antidoping community keys as to how to interpret tests and detect doping.
This work aimed to investigate the steroid profile in serum and urine in young healthy women after T administration.
In a randomized, double-blind, placebo-controlled study, 48 healthy young women were assigned to daily treatment with T cream (10 mg) or placebo (1:1) for 10 weeks. Urine and blood were collected before and at the end of treatment. Serum steroids were analyzed with liquid chromatography-tandem mass spectrometry, and urine levels of T, epitestosterone (E), and metabolites included in the Athlete Biological Passport (ABP) were analyzed with gas chromatography-tandem mass spectrometry.
In serum, T and dihydrotestosterone levels increased, whereas sex hormone-binding globulin and 17-hydroxyprogesterone decreased after T treatment as compared to placebo. In urine, T and 5α-androstanediol increased in the T group. The median T increase in serum was 5.0-fold (range, 1.2-18.2) and correlated to a 2.2-fold (range, 0.4-14.4) median increase in T/E in urine (rs = 0.76). Only 2 of the 24 women receiving T reached the T/E cutoff ratio of 4, whereas when the results were added to the ABP, 6 of 15 participants showed atypically high T/E (40%). In comparison, 22/24 women in the T group increased serum T more than 99.9% of the upper confidence interval of nontreated values.
It seems that the T/E ratio is not sufficient to detect exogenous T in women. Serum total T concentrations could serve as a complementary marker of doping.
对于外源性睾酮(T)如何影响女性的类固醇谱知之甚少。更多的知识将为反兴奋剂界提供线索,了解如何解释测试结果并检测兴奋剂。
本研究旨在调查 T 给药后年轻健康女性血清和尿液中的类固醇谱。
在一项随机、双盲、安慰剂对照研究中,48 名健康年轻女性被分配每天接受 T 霜(10mg)或安慰剂(1:1)治疗 10 周。在治疗前和治疗结束时采集尿液和血液。采用液相色谱-串联质谱法分析血清类固醇,采用气相色谱-串联质谱法分析尿液中的 T、表睾酮(E)和运动员生物护照(ABP)中包含的代谢物。
与安慰剂组相比,T 治疗后血清 T 和二氢睾酮水平升高,而性激素结合球蛋白和 17-羟孕酮水平降低。尿液中 T 和 5α-雄烷二醇在 T 组中增加。血清 T 中位数增加 5.0 倍(范围,1.2-18.2),与尿液中 T/E 中位数增加 2.2 倍(范围,0.4-14.4)相关(rs=0.76)。在接受 T 的 24 名女性中,只有 2 名达到 T/E 比值 4 的截止值,而当将结果添加到 ABP 中时,15 名参与者中有 6 名显示出异常高的 T/E(40%)。相比之下,T 组的 22/24 名女性的血清 T 增加超过未治疗值的 99.9%置信区间上限。
似乎 T/E 比值不足以检测女性的外源性 T。血清总 T 浓度可作为兴奋剂检测的补充标志物。